Phase 2a MIB-626 vs. Placebo COVID-19

Inclusion Criteria

• •A man or a woman, 18 years or older
• •Willing and able to provide informed consent, or with a legal representative who can provide informed consent with participant's assent
• •Has Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by an approved diagnostic test before randomization
• •Currently hospitalized
• •Documented increase in serum creatinine of 0.3 mg/dL or 50%-99% over baseline (baseline either based on admission serum creatinine or known pre-admission baseline, defined as most recent previous measurement)
• •Participant or legal representative has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained
• •Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act (HIPAA)
• •Patients who are receiving remdesivir as a part of their clinical care or are in clinical trials of remdesivir or other antiviral drugs may be allowed if they meet other eligibility criteria
• •Patients, who are participating in observational studies or studies of nonpharmacological interventions, will be allowed to participate
• •Not be pregnant and not planning to become pregnant over the next 6 months